Pyxis Oncology (PYXS) Competitors $1.82 -0.04 (-2.15%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.02 (+1.15%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. ALMS, PRTA, CRVS, ERAS, ITOS, SLDB, ATXS, NBTX, FULC, and CGEMShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Alumis (ALMS), Prothena (PRTA), Corvus Pharmaceuticals (CRVS), Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Its Competitors Alumis Prothena Corvus Pharmaceuticals Erasca iTeos Therapeutics Solid Biosciences Astria Therapeutics Nanobiotix Fulcrum Therapeutics Cullinan Therapeutics Pyxis Oncology (NASDAQ:PYXS) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Which has stronger valuation & earnings, PYXS or ALMS? Pyxis Oncology has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis Oncology$16.15M6.99-$77.33M-$1.60-1.14AlumisN/AN/A-$294.23MN/AN/A Do insiders and institutionals believe in PYXS or ALMS? 39.1% of Pyxis Oncology shares are owned by institutional investors. 10.6% of Pyxis Oncology shares are owned by insiders. Comparatively, 40.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer PYXS or ALMS? Pyxis Oncology currently has a consensus price target of $7.75, indicating a potential upside of 325.82%. Alumis has a consensus price target of $20.17, indicating a potential upside of 361.48%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Pyxis Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media favor PYXS or ALMS? In the previous week, Pyxis Oncology had 2 more articles in the media than Alumis. MarketBeat recorded 5 mentions for Pyxis Oncology and 3 mentions for Alumis. Alumis' average media sentiment score of 1.19 beat Pyxis Oncology's score of 1.00 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, PYXS or ALMS? Pyxis Oncology has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Alumis has a beta of -1.38, indicating that its share price is 238% less volatile than the S&P 500. Is PYXS or ALMS more profitable? Pyxis Oncology's return on equity of -68.56% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -68.56% -52.14% Alumis N/A -119.15%-92.50% SummaryPyxis Oncology beats Alumis on 7 of the 13 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.88M$2.84B$5.79B$10.15BDividend YieldN/A56.65%5.69%4.60%P/E Ratio-1.1423.5374.5925.92Price / Sales6.99534.79453.5485.33Price / CashN/A169.2537.0859.91Price / Book0.905.3712.156.29Net Income-$77.33M$32.95M$3.28B$270.77M7 Day Performance-4.71%1.31%0.99%3.36%1 Month Performance75.00%8.31%7.21%6.41%1 Year Performance-50.00%0.29%63.07%28.24% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology2.6986 of 5 stars$1.82-2.2%$7.75+325.8%-48.9%$112.88M$16.15M-1.1460ALMSAlumis3.4486 of 5 stars$4.32-4.2%$20.17+366.8%-60.1%$469.33MN/A0.00N/APositive NewsPRTAProthena3.3013 of 5 stars$8.49-0.7%$19.75+132.6%-59.7%$460.25M$10.34M-1.51130News CoverageCRVSCorvus Pharmaceuticals2.6188 of 5 stars$5.90-4.2%$15.00+154.2%+32.6%$459.01MN/A-5.8430Positive NewsERASErasca2.5665 of 5 stars$1.55-3.7%$3.71+139.6%-47.6%$456.71MN/A-3.44120ITOSiTeos Therapeutics3.4341 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences2.9954 of 5 stars$5.13-6.7%$15.00+192.4%-29.1%$428.28M$8.09M-1.83100Positive NewsATXSAstria Therapeutics3.0332 of 5 stars$7.43-1.2%$29.00+290.3%-26.2%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.6447 of 5 stars$8.71+0.1%$8.00-8.2%+94.6%$417.11M$39.18M0.00100News CoverageUpcoming EarningsShort Interest ↑Gap UpFULCFulcrum Therapeutics2.6564 of 5 stars$7.27-5.1%$7.57+4.1%-21.0%$414.34M$80M-5.96100Positive NewsShort Interest ↓CGEMCullinan Therapeutics2.2492 of 5 stars$6.84-2.1%$26.80+291.8%-63.2%$412.93MN/A-2.1230News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies ALMS Alternatives PRTA Alternatives CRVS Alternatives ERAS Alternatives ITOS Alternatives SLDB Alternatives ATXS Alternatives NBTX Alternatives FULC Alternatives CGEM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PYXS Stock Alerts